JP6978507B2 - Ｃｆｔｒ増強物質としてのピロロピリミジン - Google Patents

Ｃｆｔｒ増強物質としてのピロロピリミジン Download PDF

Info

Publication number
JP6978507B2
JP6978507B2 JP2019547579A JP2019547579A JP6978507B2 JP 6978507 B2 JP6978507 B2 JP 6978507B2 JP 2019547579 A JP2019547579 A JP 2019547579A JP 2019547579 A JP2019547579 A JP 2019547579A JP 6978507 B2 JP6978507 B2 JP 6978507B2
Authority
JP
Japan
Prior art keywords
mmol
pyrrolo
preparation
pyrimidine
reaction mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019547579A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020510668A5 (OSRAM
JP2020510668A (ja
Inventor
ジョセフ， ウォルター ストローバッハ，
デイビッド， クリストファー リンブルグ，
ジョン， ポール マティアス，
アトリ トーラレンセン，
ラジア， アルドリン デニー，
クリストフ， ウルフギャング ツァップ，
ダニエル エルバウム，
ロリ， クリム ガブリン，
イヴァン， ヴィクトロヴィッチ エフレモフ，
Original Assignee
システィック・ファイブロシス・ファンデーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by システィック・ファイブロシス・ファンデーション filed Critical システィック・ファイブロシス・ファンデーション
Publication of JP2020510668A publication Critical patent/JP2020510668A/ja
Publication of JP2020510668A5 publication Critical patent/JP2020510668A5/ja
Priority to JP2021183048A priority Critical patent/JP7360434B2/ja
Application granted granted Critical
Publication of JP6978507B2 publication Critical patent/JP6978507B2/ja
Priority to JP2023169299A priority patent/JP7592814B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
JP2019547579A 2016-11-18 2017-11-17 Ｃｆｔｒ増強物質としてのピロロピリミジン Active JP6978507B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2021183048A JP7360434B2 (ja) 2016-11-18 2021-11-10 Ｃｆｔｒ増強物質としてのピロロピリミジン
JP2023169299A JP7592814B2 (ja) 2016-11-18 2023-09-29 Ｃｆｔｒ増強物質としてのピロロピリミジン

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662423919P 2016-11-18 2016-11-18
US62/423,919 2016-11-18
PCT/US2017/062148 WO2018094137A1 (en) 2016-11-18 2017-11-17 Pyrrolopyrimidines as cftr potentiators

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021183048A Division JP7360434B2 (ja) 2016-11-18 2021-11-10 Ｃｆｔｒ増強物質としてのピロロピリミジン

Publications (3)

Publication Number Publication Date
JP2020510668A JP2020510668A (ja) 2020-04-09
JP2020510668A5 JP2020510668A5 (OSRAM) 2020-12-17
JP6978507B2 true JP6978507B2 (ja) 2021-12-08

Family

ID=62144793

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019547579A Active JP6978507B2 (ja) 2016-11-18 2017-11-17 Ｃｆｔｒ増強物質としてのピロロピリミジン
JP2021183048A Active JP7360434B2 (ja) 2016-11-18 2021-11-10 Ｃｆｔｒ増強物質としてのピロロピリミジン
JP2023169299A Active JP7592814B2 (ja) 2016-11-18 2023-09-29 Ｃｆｔｒ増強物質としてのピロロピリミジン

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021183048A Active JP7360434B2 (ja) 2016-11-18 2021-11-10 Ｃｆｔｒ増強物質としてのピロロピリミジン
JP2023169299A Active JP7592814B2 (ja) 2016-11-18 2023-09-29 Ｃｆｔｒ増強物質としてのピロロピリミジン

Country Status (22)

Country Link
US (5) US10301315B2 (OSRAM)
EP (2) EP4424311A3 (OSRAM)
JP (3) JP6978507B2 (OSRAM)
KR (2) KR102824092B1 (OSRAM)
CN (2) CN115850268B (OSRAM)
AU (2) AU2017362350B2 (OSRAM)
CA (1) CA3044050A1 (OSRAM)
CL (1) CL2019001334A1 (OSRAM)
CO (1) CO2019005993A2 (OSRAM)
CR (1) CR20190292A (OSRAM)
DO (1) DOP2019000126A (OSRAM)
EC (1) ECSP19043120A (OSRAM)
ES (1) ES2983686T3 (OSRAM)
IL (3) IL314404B1 (OSRAM)
MX (2) MX2021012639A (OSRAM)
PE (1) PE20200739A1 (OSRAM)
PH (1) PH12019501098A1 (OSRAM)
PL (1) PL3541390T3 (OSRAM)
RU (2) RU2757457C2 (OSRAM)
SG (1) SG10202106949XA (OSRAM)
UA (1) UA125400C2 (OSRAM)
WO (1) WO2018094137A1 (OSRAM)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022024023A (ja) * 2016-11-18 2022-02-08 システィック・ファイブロシス・ファンデーション Ｃｆｔｒ増強物質としてのピロロピリミジン

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ627750A (en) 2012-01-06 2016-11-25 Abide Therapeutics Inc Carbamate compounds and of making and using same
IL313498A (en) 2014-10-06 2024-08-01 Vertex Pharma Modulators of the cystic fibrosis transmembrane conductance regulator
WO2017112853A1 (en) * 2015-12-22 2017-06-29 Proteostasis Therapeutics, Inc. Methods of treating pulmonary diseases and disorders
HRP20211683T1 (hr) 2016-09-30 2022-03-04 Vertex Pharmaceuticals Incorporated Modulator transmembranskog regulatora provodljivosti cistične fibroze, farmaceutski pripravci, postupci liječenja, i postupak za pripravu modulatora
MX2021013639A (es) 2016-12-09 2022-09-30 Vertex Pharma Forma cristalina del compuesto 1, un modulador del regulador de conductancia transmembrana de fibrosis quística, procesos para su preparación, composiciones farmacéuticas del compuesto 1, y su uso en el tratamiento de fibrosis quística.
CN110300589B (zh) * 2016-12-16 2023-03-10 囊性纤维化基金会 作为cftr增效剂的双环异杂芳基衍生物
AU2018279646B2 (en) 2017-06-08 2023-04-06 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
AU2018304168B2 (en) 2017-07-17 2023-05-04 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
TWI799435B (zh) 2017-08-02 2023-04-21 美商維泰克斯製藥公司 製備化合物之製程
WO2019079760A1 (en) 2017-10-19 2019-04-25 Vertex Pharmaceuticals Incorporated CRYSTALLINE FORMS AND COMPOSITIONS OF CFTR MODULATORS
US11465985B2 (en) 2017-12-08 2022-10-11 Vertex Pharmaceuticals Incorporated Processes for making modulators of cystic fibrosis transmembrane conductance regulator
TWI810243B (zh) 2018-02-05 2023-08-01 美商維泰克斯製藥公司 用於治療囊腫纖化症之醫藥組合物
LT3752510T (lt) 2018-02-15 2023-04-11 Vertex Pharmaceuticals Incorporated Makrocikliniai junginiai kaip cistinės fibrozės transmembraninio laidumo reguliatoriaus moduliatoriai, jų farmacinės kompozicijos, jų panaudojimas cistinės fibrozės gydymui ir jų gamybos būdas
WO2019200246A1 (en) 2018-04-13 2019-10-17 Alexander Russell Abela Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
UY38630A (es) 2019-04-03 2020-10-30 Vertex Pharma Agentes moduladores del regulador de la conductancia transmembrana de la fibrosis quística
EP3980121A1 (en) * 2019-06-10 2022-04-13 Novartis AG Pyridine and pyrazine derivative for the treatment of cf, copd, and bronchiectasis
MX2022000549A (es) 2019-07-15 2022-02-10 Novartis Ag Formulaciones de (s)-3-amino-6-metoxi-n-(3,3,3-trifluoro-2-hidroxi -2-metilpropil)-5-(trifluorometil)picolinamida.
TWI867024B (zh) 2019-08-14 2024-12-21 美商維泰克斯製藥公司 囊腫纖維化跨膜傳導調節蛋白之調節劑
US11584761B2 (en) 2019-08-14 2023-02-21 Vertex Pharmaceuticals Incorporated Process of making CFTR modulators
EP4013760A1 (en) 2019-08-14 2022-06-22 Vertex Pharmaceuticals Incorporated Crystalline forms of cftr modulators
CN111138439B (zh) * 2020-01-17 2021-06-25 厦门大学 氟代吡咯并嘧啶类化合物及其制备方法和应用
US20230192700A1 (en) 2020-03-06 2023-06-22 Bayer Aktiengesellschaft Pyrazolopyrazines acting on cancers via inhibition of cdk12
KR20230052954A (ko) 2020-08-20 2023-04-20 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 점액 과다분비를 특징으로 하는 호흡기 질환의 치료 방법
AU2021397294A1 (en) 2020-12-10 2023-07-06 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
TW202425990A (zh) * 2022-11-02 2024-07-01 南韓商日東製藥股份有限公司 包含ｃｆｔｒ調節劑化合物之點眼用組成物

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ286892B6 (en) * 1992-12-17 2000-07-12 Pfizer Pyrrolopyrimidine compounds, intermediates for their preparation and pharmaceutical preparations based thereon
NZ518726A (en) 2001-05-09 2004-06-25 Warner Lambert Co Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor
AU2002310187A1 (en) 2001-05-30 2002-12-09 Lg Biomedical Institute Inhibitors of protein kinase for the treatment of disease
WO2004100868A2 (en) * 2003-04-23 2004-11-25 Abbott Laboratories Method of treating transplant rejection
EP1730148A4 (en) * 2004-02-03 2009-08-19 Abbott Lab USE OF AMINOBENZOXAZOLES AS THERAPEUTIC AGENTS
TW201307354A (zh) * 2005-12-29 2013-02-16 Abbott Lab 蛋白質激酶抑制劑
EP2007767B1 (en) * 2006-03-11 2011-11-02 Vernalis (R&D) Ltd Pyrrolopyrimidine derivatives used as hsp90 inhibitors
AU2007347115A1 (en) * 2006-04-04 2008-10-23 The Regents Of The University Of California PI3 kinase antagonists
CN101917999A (zh) * 2007-11-07 2010-12-15 弗尔德里克斯制药股份有限公司 蛋白质运输的调节
EA024252B1 (ru) 2009-01-08 2016-08-31 Кьюрис, Инк. Ингибиторы фосфоинозитид-3-киназ с цинксвязывающей группой
WO2013071232A1 (en) 2011-11-11 2013-05-16 Beta Cat Pharmaceuticals, Llc Compositions and methods for inhibition of tbl-1 binding to disease-associated molecules
US8828998B2 (en) * 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
WO2014060431A1 (en) * 2012-10-16 2014-04-24 Almirall, S.A. Pyrrolotriazinone derivatives as pi3k inhibitors
WO2015091532A1 (en) * 2013-12-19 2015-06-25 Almirall, S.A. Pyrrolopyrimidine derivatives as pi3k inhibitors
AU2017362350B2 (en) 2016-11-18 2021-12-23 Cystic Fibrosis Foundation Pyrrolopyrimidines as CFTR potentiators

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022024023A (ja) * 2016-11-18 2022-02-08 システィック・ファイブロシス・ファンデーション Ｃｆｔｒ増強物質としてのピロロピリミジン
JP7360434B2 (ja) 2016-11-18 2023-10-12 システィック・ファイブロシス・ファンデーション Ｃｆｔｒ増強物質としてのピロロピリミジン

Also Published As

Publication number Publication date
SG10202106949XA (en) 2021-07-29
RU2019118623A3 (OSRAM) 2021-03-18
US20190225621A1 (en) 2019-07-25
RU2019118623A (ru) 2020-12-21
KR102824092B1 (ko) 2025-06-25
PE20200739A1 (es) 2020-07-24
MX387203B (es) 2025-03-18
CA3044050A1 (en) 2018-05-24
IL296279A (en) 2022-11-01
ECSP19043120A (es) 2019-08-30
IL266668A (en) 2019-07-31
MX2021012639A (es) 2022-10-03
AU2017362350A1 (en) 2019-06-20
KR20230146104A (ko) 2023-10-18
IL314404A (en) 2024-09-01
EP3541390A4 (en) 2020-06-24
IL266668B (en) 2022-10-01
IL314404B1 (en) 2025-09-01
EP4424311A2 (en) 2024-09-04
JP2022024023A (ja) 2022-02-08
PH12019501098A1 (en) 2019-09-09
CO2019005993A2 (es) 2019-07-31
US20200017512A1 (en) 2020-01-16
EP3541390B1 (en) 2024-05-01
CN110337294A (zh) 2019-10-15
NZ754085A (en) 2025-05-02
IL266668B2 (en) 2023-02-01
US10301315B2 (en) 2019-05-28
US20210171534A1 (en) 2021-06-10
JP7592814B2 (ja) 2024-12-02
AU2017362350B2 (en) 2021-12-23
AU2022201816A8 (en) 2022-04-21
ES2983686T3 (es) 2024-10-24
AU2022201816B2 (en) 2024-02-15
CR20190292A (es) 2019-09-03
BR112019010167A2 (pt) 2019-09-17
CN110337294B (zh) 2022-11-01
RU2021129721A (ru) 2021-11-26
MX2019005822A (es) 2019-09-09
UA125400C2 (uk) 2022-03-02
WO2018094137A1 (en) 2018-05-24
AU2022201816A1 (en) 2022-04-07
JP7360434B2 (ja) 2023-10-12
US20230250100A1 (en) 2023-08-10
RU2757457C2 (ru) 2021-10-18
EP3541390A1 (en) 2019-09-25
CN115850268B (zh) 2025-06-27
US10494374B2 (en) 2019-12-03
JP2023182694A (ja) 2023-12-26
KR102585398B1 (ko) 2023-10-10
US20180141954A1 (en) 2018-05-24
CN115850268A (zh) 2023-03-28
DOP2019000126A (es) 2019-08-30
EP4424311A3 (en) 2024-12-18
KR20190110088A (ko) 2019-09-27
PL3541390T3 (pl) 2024-09-09
JP2020510668A (ja) 2020-04-09
EP3541390C0 (en) 2024-05-01
CL2019001334A1 (es) 2019-11-15

Similar Documents

Publication Publication Date Title
JP6978507B2 (ja) Ｃｆｔｒ増強物質としてのピロロピリミジン
CN110300589B (zh) 作为cftr增效剂的双环异杂芳基衍生物
HK40014108A (en) Pyrrolopyrimidines as cftr potentiators
HK40014108B (en) Pyrrolopyrimidines as cftr potentiators
BR112019010167B1 (pt) Compostos pirrolopirimidinas potenciadores de cftr
BR122022008825B1 (pt) Compostos pirrolopirimidinas potenciadores de cftr, composição farmacêutica que compreende os mesmos e usos terapêuticos dos ditos compostos e composição

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20190913

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20200902

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201106

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201106

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20211007

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20211019

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20211111

R150 Certificate of patent or registration of utility model

Ref document number: 6978507

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250